Full Text
EE403 Cost-Effectiveness Analysis of Nivolumab Compared to Pembrolizumab in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients

Abstract

Authors

Y Huang Y Wang K Diaby

Back to Volume 25, Supplemental Issue 7S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×